Antibody Responses Following Primary Immunization with the Recombinant Herpes Zoster Vaccine (Shingrix<sup>®</sup>) in VZV Seronegative Immunocompromised Adults

Antibody Responses Following Primary Immunization with the Recombinant Herpes Zoster Vaccine (Shingrix<sup>®</sup>) in VZV Seronegative Immunocompromised Adults

<b>Background:</b> Immunocompromised patients are at risk of severe varicella zoster virus (VZV) infection and reactivation. In VZV seronegative immunocompromised persons, live-attenuated VZV vaccination is contraindicated, thus the recombinant herpes zoster vaccine (rHZV) remains a safe...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Wessely, Ines Zwazl, Melita Poturica, Lukas Weseslindtner, Michael Kundi, Ursula Wiedermann, Angelika Wagner
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Vaccines
Subjects:
immunosuppression
hematopoietic stem cell transplantation (HSCT)
VZV seronegative
VZV subunit vaccine
adjuvanted
seroconversion
Online Access:https://www.mdpi.com/2076-393X/13/7/737
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items